Canaccord Genuity Reiterates a 'Buy' on Tranzyme (TZYM); Uli Top-line Pivotal Data Likely March/April
Tweet
Share
E-mailGet Alerts TZYM Hot Sheet
Price: $0.48 --0%
Rating Summary:
3 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 5 | New: 3
Rating Summary:
3 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 5 | New: 3
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Tranzyme (NASDAQ: TZYM) price target of $7.00.
Analyst, Ritu Baral, said, "Reiterate rating and price target on lead drug Ulimorelin (Uli) potential for Phase 3 clinical, commercial success in postoperative ileus (POI). POI is a post-op gut disorder that leads to longer hospital stays and higher healthcare costs. We believe the two Uli Phase 3 POI trials will yield positive data in March/April, an NDA submission in early 2013 and a 2014 launch. Our $7 target is based on a pNPV analysis and includes risk-adjusted potential sales of Phase 2 TZP-102 for diabetic gastroparesis."
For an analyst ratings summary and ratings history on Tranzyme click here. For more ratings news on Tranzyme click here.
Shares of Tranzyme closed at $5.04 yesterday.
Analyst, Ritu Baral, said, "Reiterate rating and price target on lead drug Ulimorelin (Uli) potential for Phase 3 clinical, commercial success in postoperative ileus (POI). POI is a post-op gut disorder that leads to longer hospital stays and higher healthcare costs. We believe the two Uli Phase 3 POI trials will yield positive data in March/April, an NDA submission in early 2013 and a 2014 launch. Our $7 target is based on a pNPV analysis and includes risk-adjusted potential sales of Phase 2 TZP-102 for diabetic gastroparesis."
For an analyst ratings summary and ratings history on Tranzyme click here. For more ratings news on Tranzyme click here.
Shares of Tranzyme closed at $5.04 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nomura/Instinet Starts Clean Max Enviro Energy Solutions (CLEANMAX:IN) at Buy
- Nomura/Instinet Downgrades RHB Bank (RHBBANK:MK) to Neutral
- Goldman Sachs Starts GenFleet Therapeutics Shanghai (2595:HK) at Buy
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
